modelSulfamethizoleAndTrimeth
Extends from Pharmacolibrary.Drugs.ATC.G.G01AE10.
Information
| name: | SulfamethizoleAndTrimethoprimCombination | |
| ATC code: | G01AE10 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 20 | L |
| clearance: | 2 | L/h |
| other parameters in model implementation | ||
This is a fixed-dose combination of two sulfonamide antibacterial agents, sulfamethizole and trimethoprim. It is used primarily for the treatment of uncomplicated urinary tract infections. These agents act synergistically to inhibit sequential steps in folic acid synthesis in bacteria. Such combinations were more commonly used in the past but are less frequently prescribed today due to resistance; however, the combination remains approved in certain countries for this indication.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult females with uncomplicated urinary tract infection. No direct published PK model for the combination, but single-compound data suggest similar PK to sulfamethizole monotherapy when coadministered with trimethoprim.
References
Zayyad, H, et al., & Paul, M (2017). Revival of old antibiotics: needs, the state of evidence and expectations. International journal of antimicrobial agents 49(5) 536–541. DOI:10.1016/j.ijantimicag.2016.11.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28162982
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)